Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,138,069 papers from all fields of science
Search
Sign In
Create Free Account
nelotanserin
Known as:
1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea
, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Narrower (1)
APD125
Broader (2)
Phenylurea Compounds
Pyrazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Big Data Challenges Targeting Proteins in GPCR Signaling Pathways; Combining PTML-ChEMBL Models and [35S]GTPγS Binding Assays.
R. Diez‐Alarcia
,
Víctor Yáñez-Pérez
,
+4 authors
H. González-Díaz
ACS chemical neuroscience
2019
Corpus ID: 204756656
G protein-coupled receptors (GPCRs), also known as 7-transmembrane receptors, are the single largest class of drug targets…
Expand
2018
2018
The Involvement of 5-HT 2A Receptor in the Regulation of Sleep and Wakefulness, and the Potential Therapeutic Use of Selective 5-HT 2A Receptor Antagonists and Inverse Agonists for the Treatment of…
J. Monti
,
S. Perumal
,
D. Spence
,
P. Torterolo
2018
Corpus ID: 79927377
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These…
Expand
2018
2018
Drug Repurposing Patent Applications October-December 2017.
H. Mucke
Assay and drug development technologies
2018
Corpus ID: 51679430
Review
2017
Review
2017
New Therapeutic Strategies for Lewy Body Dementias
L. Velayudhan
,
D. Ffytche
,
C. Ballard
,
D. Aarsland
Current Neurology and Neuroscience Reports
2017
Corpus ID: 3739100
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available…
Expand
Review
2017
Review
2017
Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.
P. Huot
,
V. Sgambato-Faure
,
S. Fox
,
A. McCreary
ACS chemical neuroscience
2017
Corpus ID: 3521369
Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the…
Expand
Review
2017
Review
2017
A Phase 2 Study of Nelotanserin, a Novel 5HT2A Receptor Inverse Agonist, in Dementia with Lewy Bodies and Parkinson’s Disease Dementia Subjects Experiencing Visual Hallucinations (P6.088)
W. Wen
,
S. Ramaswamy
,
Kunal S. Kishnani
,
G. Ramaswamy
,
L. Friedhoff
2017
Corpus ID: 80597987
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations…
Expand
2016
2016
The Effects of Benzodiazepine and Nonbenzodiazepine Agents, Ramelteon, Low-dose Doxepin, Suvorexant, and Selective Serotonin 5-HT2A Receptor Antagonists and Inverse Agonists on Sleep and Wakefulness
J. Monti
,
P. Torterolo
,
Seithikurippu R Pandi-Perumal
2016
Corpus ID: 16022017
Several agents are known to improve sleep induction and/or maintenance in patients with insomnia disorder. These include the…
Expand
Review
2011
Review
2011
Serotonin control of sleep-wake behavior.
J. Monti
Sleep medicine reviews
2011
Corpus ID: 29773003
2010
2010
Discovery of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxyphenyl]-3-(2,4-difluorophenyl)urea (nelotanserin) and related 5-hydroxytryptamine2A inverse agonists for the treatment of insomnia.
B. Teegarden
,
Hongmei Li
,
+18 authors
H. Al-Shamma
Journal of medicinal chemistry
2010
Corpus ID: 22983089
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily…
Expand
2010
2010
Nelotanserin, a Novel Selective Human 5-Hydroxytryptamine2A Inverse Agonist for the Treatment of Insomnia
H. Al-Shamma
,
C. Anderson
,
+8 authors
D. Behan
Journal of Pharmacology and Experimental…
2010
Corpus ID: 2759858
5-Hydroxytryptamine (5-HT)2A receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE